Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$7.85 -0.3%	$7.62	$5.00 ▼ $45.20	$456.73M	1.34	1.49 million shs	648,414 shs
MNMD Mind Medicine (MindMed)	$6.23 -3.1%	$6.24	$4.70 ▼ $10.44	$484.62M	2.54	1.39 million shs	717,589 shs
NMRA Neumora Therapeutics	$0.76 +1.1%	$1.10	$0.62 ▼ $17.19	$121.23M	2.89	1.49 million shs	909,038 shs
SIGA SIGA Technologies	$6.50 +0.3%	$5.77	$4.95 ▼ $12.83	$464.37M	1.03	778,615 shs	742,305 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	0.00%	+0.19%	+19.05%	-38.48%	-83.08%
MNMD Mind Medicine (MindMed)	0.00%	+7.97%	-3.11%	-10.87%	-26.36%
NMRA Neumora Therapeutics	0.00%	+17.12%	-31.14%	-64.27%	-92.10%
SIGA SIGA Technologies	0.00%	+8.51%	+16.70%	+0.78%	-24.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNA Ginkgo Bioworks	0.5929 of 5 stars	0.8	1.0	1.4	2.5	1.3
MNMD Mind Medicine (MindMed)	2.5046 of 5 stars	3.6	3.0	2.9	0.8	0.6
NMRA Neumora Therapeutics	3.3331 of 5 stars	4.1	1.0	2.9	3.3	1.3
SIGA SIGA Technologies	1.8828 of 5 stars	0.0	1.0	3.5	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	1.60	Reduce	$4.58	-41.72% Downside
MNMD Mind Medicine (MindMed)	3.23	Buy	$25.11	303.07% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,125.84% Upside
SIGA SIGA Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NMRA, MNMD, DNA, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00
3/10/2025	NMRA Neumora Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/7/2025	MNMD Mind Medicine (MindMed)	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$27.00 ➝ $16.00
3/7/2025	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
3/7/2025	NMRA Neumora Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/7/2025	NMRA Neumora Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00 ➝ $2.00
3/4/2025	NMRA Neumora Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$4.00 ➝ $4.00
3/4/2025	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $18.00
3/4/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
2/14/2025	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$227.04M	2.01	N/A	N/A	$21.93 per share	0.36
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$3.07 per share	N/A
SIGA SIGA Technologies	$138.72M	3.35	$1.03 per share	6.34	$2.77 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$892.87M	-$10.68	N/A	N/A	N/A	-298.78%	-58.54%	-34.24%	5/8/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$95.73M	-$2.08	N/A	N/A	N/A	N/A	-47.56%	-35.55%	5/8/2025 (Estimated)
NMRA Neumora Therapeutics	-$235.93M	-$1.53	N/A	N/A	N/A	N/A	-73.63%	-68.97%	5/6/2025 (Estimated)
SIGA SIGA Technologies	$68.07M	$0.82	5.42	5.20	N/A	49.33%	49.06%	38.72%	5/6/2025 (Estimated)

Latest NMRA, MNMD, DNA, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	N/A	N/A	N/A	N/A	N/A
3/11/2025	Q4 2024	SIGA SIGA Technologies	N/A	$0.63	N/A	$0.63	N/A	$81.40 million
3/6/2025	Q4 2024	MNMD Mind Medicine (MindMed)	-$0.33	-$0.41	-$0.08	-$0.41	N/A	N/A
3/6/2025	Q4 2024	NMRA Neumora Therapeutics	-$0.46	-$0.37	+$0.09	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA SIGA Technologies	N/A	N/A	N/A	N/A	N/A

Latest NMRA, MNMD, DNA, and SIGA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA SIGA Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	5.79	5.79
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00
NMRA Neumora Therapeutics	N/A	10.98	10.98
SIGA SIGA Technologies	N/A	8.10	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
MNMD Mind Medicine (MindMed)	27.91%
NMRA Neumora Therapeutics	47.65%
SIGA SIGA Technologies	55.40%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	9.72%
MNMD Mind Medicine (MindMed)	2.26%
NMRA Neumora Therapeutics	26.40%
SIGA SIGA Technologies	1.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	58.03 million	51.89 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.37 million	71.68 million	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.91 million	Optionable
SIGA SIGA Technologies	40	71.44 million	70.31 million	Optionable

NMRA, MNMD, DNA, and SIGA Headlines

Recent News About These Companies

Here's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market Today

April 25 at 6:50 PM | zacks.com

Siga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to Know

April 23, 2025 | zacks.com

SIGA Technologies Target of Unusually High Options Trading (NASDAQ:SIGA)

April 19, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should Know

April 17, 2025 | msn.com

LSV Asset Management Has $974,000 Stock Holdings in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 17, 2025 | marketbeat.com

3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield (SIGA)

April 16, 2025 | dividendstocks.com

Siga Technologies Inc. (SIGA) Falls More Steeply Than Broader Market: What Investors Need to Know

April 15, 2025 | zacks.com

ExodusPoint Capital Management LP Makes New Investment in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 15, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Position Cut by Arrowstreet Capital Limited Partnership

April 12, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Announces $0.60 Special Dividend

April 10, 2025 | marketbeat.com

Siga Technologies Shares Climb on Special Dividend

April 8, 2025 | marketwatch.com

SIGA Declares Special Cash Dividend of $0.60 Per Share

April 8, 2025 | globenewswire.com

Prudential Financial Inc. Has $1.14 Million Stock Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 8, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Declines More Than Market: Some Information for Investors

April 7, 2025 | zacks.com

SIGA Technologies: Asymmetric Upside, If 2025 Goes Right

April 7, 2025 | seekingalpha.com

KLP Kapitalforvaltning AS Purchases New Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 5, 2025 | marketbeat.com

American Century Companies Inc. Buys 114,270 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

April 5, 2025 | marketbeat.com

SIGA Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)

April 4, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Holdings Lessened by First Wilshire Securities Management Inc.

April 3, 2025 | marketbeat.com

AltraVue Capital LLC Buys 326,630 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

April 2, 2025 | marketbeat.com

Brokers Offer Predictions for SIGA FY2025 Earnings

March 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA, MNMD, DNA, and SIGA Company Descriptions

Ginkgo Bioworks NYSE:DNA

$7.85 -0.02 (-0.25%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$7.90 +0.05 (+0.65%)

As of 04/25/2025 08:00 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Mind Medicine (MindMed) NASDAQ:MNMD

$6.23 -0.20 (-3.11%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$6.27 +0.04 (+0.64%)

As of 04/25/2025 07:53 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Neumora Therapeutics NASDAQ:NMRA

$0.76 +0.01 (+1.07%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$0.77 +0.01 (+1.65%)

As of 04/25/2025 07:51 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

SIGA Technologies NASDAQ:SIGA

$6.50 +0.02 (+0.31%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$6.54 +0.04 (+0.62%)

As of 04/25/2025 07:45 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time